1
=
-
Eli Lilly & Co.
As of May 21, 2026 at 10:03 UTC
Chart
About Eli Lilly & Co.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Market Statistics
Trading Metrics
How to Buy LLY
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy LLY
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesEli Lilly's oral GLP-1 medication Foundayo showed strong results in weight-loss maintenance trials, supporting the company's two-pronged strategy to capture market share. The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable Zepbound to oral Foundayo retained 80% of their weight loss after 52 weeks, significantly outperforming those who discontinued GLP-1s entirely. While Foundayo lags behind Novo Nordisk's Wegovy pill in initial weight loss efficacy, Lilly's advantage in maintenance therapy and lack of dietary restrictions positions it competitively. Lilly shares rose 2.4% on the data release, with Wall Street analysts maintaining a consensus price target of $1,218, implying over 20% upside.
The GLP-1 weight-loss drug market is booming with three main investment options. Eli Lilly leads with strong Mounjaro and Zepbound sales growth but trades at an expensive 35x P/E ratio. Novo Nordisk, the first-to-market player, faces pricing pressures and patent expirations but offers a compelling turnaround opportunity at a 10x P/E after a 45% stock decline. Viking Therapeutics represents a high-risk, high-reward bet for aggressive investors with GLP-1 drugs in clinical trials.
The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.
President Trump purchased up to $680,000 in Eli Lilly shares and $250,000-$500,000 in West Pharmaceutical shares in early 2026, with purchases coinciding with new Medicare policies favoring GLP-1 obesity drugs. Eli Lilly was selected for a CMS pilot program offering GLP-1 drugs at $50/month. The Trump Organization stated investments are independently managed through discretionary accounts.
Eli Lilly's stock has surged above $1,000 following strong Q1 results driven by its dominance in weight-loss and diabetes markets. Despite increasing competition from rivals like Novo Nordisk and Amgen, the company maintains advantages through superior pipeline candidates like Retatrutide and diversified revenue streams in oncology, immunology, and neuroscience. AI-powered drug development efforts could further accelerate growth, potentially enabling the stock to double within six years.
